Advertisement
Drugs & Targets

BMS, Enterome collaborate on microbiome-derived biomarkers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

BRISTOL-MYERS SQUIBB and Enterome SA entered into an immuno-oncology focused collaboration agreement for the discovery and development of microbiome-derived biomarkers, drug targets and bioactive molecules to be developed as potential companion diagnostics and therapeutics for cancer. The collaboration will combine Bristol-Myers Squibb’s expertise in the discovery and development of novel immunotherapies with Enterome’s proprietary metagenomic...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

In Brief

Fenghuang “Frank” Zhan invested in inaugural Bart Barlogie Chair for Myeloma Research

Zhan, seated, with Steven Webber (left), dean of the College of Medicine and executive vice chancellor at UAMS, and UAMS chancellor Cam Patterson (right).The University of Arkansas for Medical Sciences College of Medicine invested Fenghuang “Frank” Zhan, a tenured professor of medicine and the research director of the UAMS Winthrop P. Rockefeller Cancer Institute’s Myeloma Center, in the Bart Barlogie Chair for Myeloma Research during a March 13 ceremony. 
Advertisement
Advertisement